Latest
Neurotrophic keratitis acquires recombinant nerve growth factor therapy
Cenegermin (recombinant nerve growth factor) maturity, follow-on programs, and structured corneal-care pathways are reshaping neurotrophic keratitis management.
Retinal vein occlusion therapy options widen past first-generation anti-VEGF
Faricimab and high-dose aflibercept extension, structured macular edema management, and emerging mechanism programs are reshaping retinal vein occlusion management.
Proliferative diabetic retinopathy therapy reshapes around anti-VEGF
Anti-VEGF first-line for proliferative diabetic retinopathy, panretinal photocoagulation as alternative or combination, and emerging mechanism programs are reshaping PDR management.
Allergic conjunctivitis therapy widens past topical antihistamines
Topical multi-action options, novel mechanism programs, and emerging biologic-pathway therapy are reshaping allergic conjunctivitis management.
By signal pillar
Market access & reimbursement
1Scientific
13Neurotrophic keratitis acquires recombinant nerve growth factor therapy
Cenegermin (recombinant nerve growth factor) maturity, follow-on programs, and structured corneal-care pathways are reshaping neurotrophic keratitis management.
Retinal vein occlusion therapy options widen past first-generation anti-VEGF
Faricimab and high-dose aflibercept extension, structured macular edema management, and emerging mechanism programs are reshaping retinal vein occlusion management.
Proliferative diabetic retinopathy therapy reshapes around anti-VEGF
Anti-VEGF first-line for proliferative diabetic retinopathy, panretinal photocoagulation as alternative or combination, and emerging mechanism programs are reshaping PDR management.
Allergic conjunctivitis therapy widens past topical antihistamines
Topical multi-action options, novel mechanism programs, and emerging biologic-pathway therapy are reshaping allergic conjunctivitis management.
Presbyopia pharmacological options widen past pilocarpine
Pilocarpine maturity, follow-on miotic-class programs, and emerging non-miotic mechanism programs are reshaping presbyopia management.
Keratoconus therapy widens past corneal cross-linking
Corneal cross-linking adoption, intracorneal ring segment maturity, and emerging custom cross-linking and topography-guided treatment are reshaping keratoconus management.
Thyroid eye disease therapy grows past teprotumumab
Teprotumumab maturity plus follow-on IGF-1R-targeted programs and novel non-IGF-1R mechanism classes are restructuring thyroid eye disease management.
Inherited retinal disease gene therapy widens past RPE65
X-linked retinitis pigmentosa, choroideremia, and additional inherited retinal disease gene therapy programs are reading out.
Choroidal melanoma therapy options widen
Approved tebentafusp and emerging programs are creating the first systemic therapy options for metastatic choroidal melanoma.
Diabetic eye disease as a screening problem
Therapy for diabetic retinopathy and macular edema is well-established; the operational story is whether at-risk patients get screened in time.
Durable anti-VEGF and the injection burden problem
Longer-acting anti-VEGF agents are reframing how routine retinal-disease maintenance gets delivered.
Geographic atrophy: a slow-build category
Geographic atrophy therapies are establishing themselves as a routine retinal care category.
AI in routine ophthalmology diagnostics
AI-assisted retinal imaging and triage tools are quietly becoming part of routine workflow in ophthalmology.
Real-world evidence
3Glaucoma drug-delivery implant uptake reveals the procedure-room workflow constraint
Sustained-release glaucoma drug-delivery implants are addressing the chronic adherence problem that has characterised glaucoma management for decades. Real-world uptake reveals the procedure-room workflow as the principal access constraint.
Diabetic macular oedema commercial dynamics are being reshaped by the long-duration anti-VEGF class
The long-duration anti-VEGF class (faricimab, high-dose aflibercept) is reshaping diabetic macular oedema commercial dynamics through extended dosing intervals that reduce patient burden. The implications for the established anti-VEGF class, the steroid implant alternatives, and the adjacent retinal pipeline are material.
Geographic atrophy therapy uptake reveals the disease-monitoring infrastructure gap
Real-world uptake of complement C3 and C5 inhibitors for geographic atrophy has been slower and more variable than the pivotal trial benefit profile would have predicted. The drivers are disease-monitoring infrastructure, intravitreal-injection capacity, and the patient-and-clinician decision frame around a slowly progressive condition.